
BioNTech SE BNTX
$ 108.91
-0.02%
Annual report 2024
added 01-24-2026
BioNTech SE Total Assets 2011-2026 | BNTX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets BioNTech SE
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.5 B | 23 B | 23.3 B | 15.8 B | 2.32 B | 798 M | 653 M | 375 M | 390 M | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23.3 B | 375 M | 9.91 B |
Quarterly Total Assets BioNTech SE
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 15.8 B | - | - | - | 2.32 B | - | - | - | 798 M | - | - | - | 653 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 15.8 B | 653 M | 4.9 B |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | ||
|
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M | ||
|
Amarin Corporation plc
AMRN
|
832 M | $ 14.58 | -2.93 % | $ 5.94 B | ||
|
Aptorum Group Limited
APM
|
16.1 M | $ 0.82 | -2.71 % | $ 4.47 M | ||
|
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | ||
|
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | ||
|
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | ||
|
Adagene
ADAG
|
89.3 M | $ 2.99 | 0.17 % | $ 168 M | ||
|
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | ||
|
AlloVir
ALVR
|
119 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | ||
|
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | ||
|
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.48 | -0.78 % | $ 8.37 B | ||
|
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | ||
|
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | ||
|
Aptose Biosciences
APTO
|
10.1 M | - | -45.71 % | $ 1.2 M | ||
|
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | ||
|
Athira Pharma
ATHA
|
58.8 M | - | - | $ 269 M | ||
|
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | ||
|
Aeglea BioTherapeutics
AGLE
|
608 M | - | - | $ 1.01 B | ||
|
Burford Capital Limited
BUR
|
3.11 B | $ 9.14 | -1.14 % | $ 1.47 B | ||
|
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | ||
|
Brickell Biotech
BBI
|
11.6 M | - | -5.38 % | $ 6.06 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - | ||
|
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | ||
|
Ascendis Pharma A/S
ASND
|
1.18 B | $ 217.62 | -2.93 % | $ 5 B | ||
|
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
62.2 M | - | -13.39 % | $ 1.45 M | ||
|
Codexis
CDXS
|
149 M | $ 1.2 | -4.4 % | $ 88.1 M | ||
|
Arena Pharmaceuticals
ARNA
|
785 M | - | -6.81 % | $ 3.04 B | ||
|
BeiGene, Ltd.
BGNE
|
5.92 B | - | 0.49 % | $ 251 B | ||
|
Aridis Pharmaceuticals
ARDS
|
14.7 M | - | 17.91 % | $ 11.1 M | ||
|
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12 M | - | -10.17 % | $ 12.2 K | ||
|
Athersys
ATHX
|
60.2 M | - | 3.77 % | $ 22.4 M | ||
|
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | ||
|
Avenue Therapeutics
ATXI
|
2.67 M | - | -52.27 % | $ 4.45 M | ||
|
Baudax Bio
BXRX
|
10 M | - | 0.59 % | $ 63 K | ||
|
Cabaletta Bio
CABA
|
254 M | $ 2.54 | -2.38 % | $ 2.97 M | ||
|
Calithera Biosciences
CALA
|
64.8 M | - | -10.95 % | $ 876 K | ||
|
Autolus Therapeutics plc
AUTL
|
783 M | $ 1.4 | -2.45 % | $ 357 M | ||
|
Amneal Pharmaceuticals
AMRX
|
3.5 B | $ 14.71 | -0.34 % | $ 4.55 B | ||
|
AIkido Pharma
AIKI
|
47.1 M | - | 1.93 % | $ 17.4 M | ||
|
AVROBIO
AVRO
|
101 M | - | 1083.1 % | $ 745 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
9.12 M | $ 4.28 | -1.34 % | $ 9.31 B | ||
|
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M |